Chart of the Day: ImmunoCellular Therapeutics

According to Yahoo!Finance, “ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers.”

image

The Study of Failure

"'Failure, that is, struck to the core of one's identity; as Cathy Matson explains in a succinct phrase, ‘Business setbacks were attributed to personal failure rather than to social forces'(KOPEC, ANDREW. “Irving, Ruin, and Risk.” Early American Literature, vol. 48, no. 3, 2013, pp. 709–735. JSTOR, JSTOR, www.jstor.org/stable/24476334.)"

Leave a Reply

Your email address will not be published. Required fields are marked *